The FDA announced on Aug. 22, 2024, that ProRx LLC is recalling Tirzepatide multidose injection vials due to a lack of assurance of sterility. According to the FDA, owners should stop using the product immediately.
How to tell if you have it
- Brand: ProRx
- Product: Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials
- NDC: 84139-210-01
- Lot #: ProRx040924-1
- BUD: 10/08/2024
The hazard
The recall addresses a lack of assurance of sterility in the compounded prescription product. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show ProRx LLC has one other recall on record since Oct. 15, 2025, for Semaglutide Injection due to a lack of assurance of sterility. Other recent recalls of similar products include New Life Pharma Tirzepatide Inj 15mg Vial Recall (Feb. 26, 2026), New Life Pharma Tirzepatide 10mg Vial Recall (Feb. 26, 2026), and Reliance Pemetrexed Injection Recall (June 24, 2026).